Holkira (ombitasvir/paritaprevir/rtonavir with dasabuvir) and Harvoni (ledipasvir/sofosbuvir) for chronic hepatitis C a review of the clinical evidence
The treatment of chronic hepatitis C (CHC) using the all oral, interferon-free regimen has potential advantages compared with interferon-based regimens. This report reviews the evidence of clinical effectiveness and safety of Harvoni and Holkira Pak for the management of CHC genotype 1, which may as...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[Ottawa]
Canadian Agency for Drugs and Technologies in Health
16 January 2015, 2015
|
| Series: | Rapid response report : summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The treatment of chronic hepatitis C (CHC) using the all oral, interferon-free regimen has potential advantages compared with interferon-based regimens. This report reviews the evidence of clinical effectiveness and safety of Harvoni and Holkira Pak for the management of CHC genotype 1, which may assist in healthcare funding decision-making in the context of the publicly funded healthcare system. Due to the complex generic names, the trade names of these therapies will be used in the review for clarity |
|---|---|
| Item Description: | Title from PDF caption |
| Physical Description: | 1 PDF file (44 pages) |